Skip to Content

What is Tagrisso used for?

Medically reviewed by Last updated on Oct 7, 2019.

Official Answer


Tagrisso (generic name: osimertinib), manufactured by AstraZeneca Pharmaceuticals, is a EGFR tyrosine kinase inhibitor used for the treatment of advanced non-small cell lung cancer (NSCLC).

Tagrisso is approved for the population of patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed while receiving or after EGFR TKI therapy. The FDA also approved the companion diagnostic cobas EGFR Mutation Test v2 to detect EGFR mutations in patients with non-small cell lung cancer, including T790M.

Tagrisso tablets are taken orally once daily, with or without food.

The most common side effects of Tagrisso include diarrhea, and skin and nail conditions such as dry skin, rash and infection or redness around the fingernails.

Related Medical Questions

Drug Information

Related Support Groups